1. Home
  2. SGN vs KALA Comparison

SGN vs KALA Comparison

Compare SGN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Signing Day Sports Inc.

SGN

Signing Day Sports Inc.

HOLD

Current Price

$1.13

Market Cap

4.7M

Sector

N/A

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.60

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGN
KALA
Founded
2019
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
5.1M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
SGN
KALA
Price
$1.13
$0.60
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
254.8K
21.5M
Earning Date
11-12-2025
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$366,344.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.61
52 Week High
$7.24
$20.60

Technical Indicators

Market Signals
Indicator
SGN
KALA
Relative Strength Index (RSI) 41.01 34.58
Support Level $1.17 $0.67
Resistance Level $1.32 $0.86
Average True Range (ATR) 0.13 0.24
MACD 0.01 0.07
Stochastic Oscillator 41.46 0.16

Price Performance

Historical Comparison
SGN
KALA

About SGN Signing Day Sports Inc.

Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: